Brystol Myers rises after BofA upgrades rating to "buy"

Drug maker Brystol Myers Squibb's BMY.N shares rise 2.4% to $53.64 after BofA Global Research upgrades rating to "buy" from "neutral"

Brokerage raises PT to $61 from $52, a 16.4% upside to stock's last close

Attributes upgrade to co's R&D pipeline outlook; says 2026 a big year for BMY's anti-psychotic drug, Cobenfy

"We estimate Cobenfy, despite a slow first year launch, can get to $3bn US peak in schizophrenia alone" - BofA

10 of 30 brokerages rate the stock "buy" or higher, 18 "hold" and 2 "sell"; median PT is $54 - LSEG data

Including session moves, stock down 5.3% YTD